Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RecruitingPhase 2Healthy volunteers welcome
Who can join
Ages 30 to 60 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Body mass index (BMI) 30-45 kg/m2 * 30-60 years of age at randomization * Evidence of arterial stiffening (defined as Carotid femoral PWV\>age-predicted) at screening visit (PMID: 20530030) Exclusion Criteria: * Unable to provide consent * Diabetes mellitus * Uncontrolled hypertension (\>180/90mmHg) or systolic \<100mmHg at screening visit * Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke * Diagnosis of chronic kidney disease * Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin) * Excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women) * Use of GLP-1 analogs or SGLT2 inhibitors * Use of hormone replacement therapy * Use of pharmacological therapy for weight loss * Body weight changes \>10% within the past 6 months * History of hypersensitivity to nitrates * History of ketoacidosis * History of recurrent UTIs or mycotic genital infections * Use of anticoagulants * Change in anti-hypertensive medication regimen (if in use) during the last 90 days * Pregnancy
About the study
The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.
What is being tested
- Empagliflozin (drug)
- Placebo (drug)
Sponsor: VA Office of Research and Development · Participants: 50 · Started: May 30, 2025
Contact the study team
- Jaume Padilla Parellada, PhD · Phone: (573) 814-6552
- Katherine M Burr · Phone: (573) 814-6550
Official record on ClinicalTrials.gov — NCT06745063
Locations in the U.S.
| Missouri | Harry S. Truman Memorial, Columbia, MO, Columbia |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.